Proteomics in IDH-mutated diffuse lower-grade glioma: a scoping review.

ABSTRACT:

Background

Therapeutic options and biomarkers for isocitrate dehydrogenase-mutated (IDHmut) diffuse lower-grade glioma (dLGG), WHO grade 2-3, are limited. Global quantitative proteomics has aided the discovery of novel markers and drug targets across various pathologies. This review aimed to summarize current proteomic findings in IDHmut dLGG.

Methods

PubMed, Embase, and Scopus were searched following PRISMA-ScR guidelines. Studies examining quantitative proteomics in IDHmut dLGG with liquid chromatography-mass spectrometry in adult human samples were included. Studies with only high-grade gliomas, without IDHmut, using xenografts, or cell line samples, and reviews were excluded.

Results

In total, 1,902 records were identified; 85 full-texts were retrieved, and 13 met

SUBMITTER: Kihlstedt CJ 

PROVIDER: S-EPMC12932947 | biostudies-literature | 2026 Jan-Dec

REPOSITORIES: biostudies-literature